Slide 1: Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic NSCLC: Preliminary Results of EVOKE-02
Byoung Chul Cho, Yonsei Cancer Center, Republic of Korea 1 DRAFT Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study Byoung Chul Cho,1 Manuel Cobo Dols,2 Roxana Reyes Cabanillas,3 David Vicente,4 Jose Fuentes Pradera,5 Salvator
Slide 2: Introduction
Byoung Chul Cho, Yonsei Cancer Center, Republic of Korea 2 DRAFT Introduction • PD-(L)1 inhibitor-based regimens have been established as the standard-of-care 1L treatment for mNSCLC,1,2 and novel combination therapies are needed to further improve outcomes • Sacituzumab govitecan is a Trop-2–direct
Slide 3: EVOKE-02: An Open-Label, Multicohort Phase 2 Study
Byoung Chul Cho, Yonsei Cancer Center, Republic of Korea 3 DRAFT aDose de-escalation safety run-in period to determine the RP2D of SG for Cohorts C and D. bCarboplatin dosed as area under the concentration versus time curve 5. cPer RECIST v1.1. ECOG PS, Eastern Cooperative Oncology Group performance
Slide 4: Patient Baseline Characteristics, Exposure, and Disposition
Byoung Chul Cho, Yonsei Cancer Center, Republic of Korea 4 DRAFT aDisease stage at diagnosis: Stage I-III (Cohort A, n = 5; Cohort B, n = 5). bThe PD-L1 IHC 22C3 pharmDx assay was required for PD-L1 testing. Local and central tumor tissue testing were allowed. ECOG PS, Eastern Cooperative Oncology G
Slide 5: Efficacy by Investigator Assessment
Byoung Chul Cho, Yonsei Cancer Center, Republic of Korea 5 DRAFT Only patients enrolled ≥ 13 weeks prior to the data cutoff date (16 June 2023) were included in the efficacy analysis. aPatients without tumor assessment (Cohort A, n = 1; Cohort B, n = 5). bORR was defined as BOR of CR + PR. c DCR was
Slide 6: Waterfall Plot for Change in Target Lesions
Byoung Chul Cho, Yonsei Cancer Center, Republic of Korea 6 DRAFT Only patients enrolled ≥ 13 weeks prior to the data cutoff date (16 June 2023) were included in the efficacy analysis. PD-L1, programmed death ligand 1; TPS, tumor proportion score. Waterfall Plot for Change in Target Lesions Total Bes
Slide 7: Depth and Duration of Response
Byoung Chul Cho, Yonsei Cancer Center, Republic of Korea 7 DRAFT Only patients enrolled ≥ 13 weeks prior to the data cutoff date (16 June 2023) were included in the efficacy analysis. PD-L1, programmed death ligand 1; Pembro, pembrolizumab; SG, sacituzumab govitecan; TPS, tumor proportion score. Dep
Slide 8: Safety Summary
Byoung Chul Cho, Yonsei Cancer Center, Republic of Korea 8 DRAFT All patients who received ≥ 1 dose of study treatment were included in the safety analysis. Pembro, pembrolizumab; SG, sacituzumab govitecan; TEAE, treatment-emergent adverse event. Safety Summary Safety-evaluable patients, n (%) Total
Slide 9: Immune-mediated and Common Treatment-Emergent Adverse Events
Byoung Chul Cho, Yonsei Cancer Center, Republic of Korea 9 DRAFT All patients who received ≥ 1 dose of study treatment were included in the safety analysis. aGrade 3 pneumonitis was the highest grade observed to date (n = 2). Pembro, pembrolizumab; TEAE, treatment-emergent adverse event. • Immune-me
Slide 10: Conclusions
Byoung Chul Cho, Yonsei Cancer Center, Republic of Korea 10 DRAFT 1L, first-line; DCR, disease control rate; DOR, duration of response; mNSCLC, metastatic non-small cell lung cancer; ORR, objective response rate; PD-L1, programmed death ligand 1; Pembro, pembrolizumab; SG, sacituzumab govitecan; TEA
Slide 11: Acknowledgments
Byoung Chul Cho, Yonsei Cancer Center, Republic of Korea 11 DRAFT Acknowledgments • We would like to thank the patients, their caregivers, and families for their participation and commitment to clinical research • Thank you to the clinical trial investigators and their team members, without whom thi